Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
Andrew Blumenfeld, Benjamin Frishberg, Jack Schim, et al.
Pain and Therapy (2021) Vol. 10, Iss. 2, pp. 809-826
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Andrew F. Russo, Debbie L. Hay
Physiological Reviews (2022) Vol. 103, Iss. 2, pp. 1565-1644
Open Access | Times Cited: 157
CGRP-targeted medication in chronic migraine - systematic review
Renato Oliveira, Raquel Gil‐Gouveia, Francesca Puledda
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 16
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score
Luigi Francesco Iannone, Davide Fattori, Silvia Benemei, et al.
CNS Drugs (2022) Vol. 36, Iss. 2, pp. 191-202
Open Access | Times Cited: 62
Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
Laszlo Mechtler, Nicolas Saikali, Jennifer McVige, et al.
Frontiers in Neurology (2022) Vol. 12
Open Access | Times Cited: 42
Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy: The multicenter prospective cohort GARLIT study
Fabrizio Vernieri, Nicoletta Brunelli, Marilena Marcosano, et al.
European Journal of Neurology (2022) Vol. 30, Iss. 1, pp. 224-234
Open Access | Times Cited: 38
Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study
Licia Grazzi, Riccardo Giossi, Danilo Antonio Montisano, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 10
Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
Antun R. Pavelić, Christian Wöber, Franz Riederer, et al.
Cells (2022) Vol. 12, Iss. 1, pp. 143-143
Open Access | Times Cited: 37
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
Maurice T. Driessen, Joshua M. Cohen, Stephen F. Thompson, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 33
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study
Raffaele Ornello, Carlo Baraldi, Simona Guerzoni, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 32
Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale
Fred Cohen, Hsiangkuo Yuan, Stephen D. Silberstein
BioDrugs (2022) Vol. 36, Iss. 3, pp. 341-358
Open Access | Times Cited: 28
Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine
Damiana Scuteri, Paolo Tonin, Pierluigi Nicotera, et al.
Toxins (2022) Vol. 14, Iss. 8, pp. 529-529
Open Access | Times Cited: 28
Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis
Giorgio Lambru, Valeria Caponnetto, Bethany Hill, et al.
Neurotherapeutics (2023) Vol. 20, Iss. 5, pp. 1284-1293
Open Access | Times Cited: 17
Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review
Jean Schoenen, Annelies Van Dycke, Jan Versijpt, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 17
OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine
Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
Toxins (2022) Vol. 14, Iss. 12, pp. 847-847
Open Access | Times Cited: 24
The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine
Fred Cohen, Hsiangkuo Yuan, Ellen Michelle Gibson DePoy, et al.
Neurotherapeutics (2022) Vol. 19, Iss. 3, pp. 922-930
Open Access | Times Cited: 23
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study
Fabrizio Vernieri, Nicoletta Brunelli, Simona Guerzoni, et al.
Journal of Neurology (2023) Vol. 270, Iss. 11, pp. 5436-5448
Closed Access | Times Cited: 13
Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review
Ann Murray, Jennifer I. Stern, Carrie E. Robertson, et al.
Current Pain and Headache Reports (2022) Vol. 26, Iss. 10, pp. 783-794
Closed Access | Times Cited: 21
Pharmacologic prevention of migraine
Velina Tzankova, Werner J. Becker, Tommy Lik Hang Chan
Canadian Medical Association Journal (2023) Vol. 195, Iss. 5, pp. E187-E192
Open Access | Times Cited: 12
Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review
Andrew Blumenfeld, Richard B. Lipton, Stephen D. Silberstein, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 5, pp. 1533-1551
Open Access | Times Cited: 11
Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis
Anna P. Andreou, Matteo Fuccaro, Bethany Hill, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 18
Towards precision medicine in migraine: Recent therapeutic advances and potential biomarkers to understand heterogeneity and treatment response
Gabriella Juhász, Kinga Gecse, Dániel Baksa
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108523-108523
Open Access | Times Cited: 10
Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
Aubrey Manack Adams, Susan Hutchinson, Ella Engstrom, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 9
Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review
Amira Salim, Elise Hennessy, Claire Sonneborn, et al.
CNS Drugs (2024) Vol. 38, Iss. 6, pp. 481-491
Open Access | Times Cited: 3
Combining treatments for migraine prophylaxis: the state-of-the-art
Lanfranco Pellesi, David García‐Azorín, Eloísa Rubio‐Beltrán, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 3
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany
Andreas Straube, Philipp Stude, Charly Gaul, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top